Citi analyst Joanne Wuensch raised the firm’s price target on Intuitive Surgical to $512 from $462 and keeps a Buy rating on the shares. The analyst also opened a “30-day negative catalyst watch” on the name into earnings. While Citi believes Intuitive will at least deliver on expectations and potentially above, it finds it it possible that the da Vinci 5 “excitement has risen too far too fast which may lead to a weak post-print stock move.” In the near-term investors “may be getting in over their skis for the DV5 ramp,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- ISRG, PFE, or DXCM: Which Healthcare Stock Could Generate the Highest Returns?
- Intuitive Surgical price target raised to $425 from $385 at Evercore ISI
- Intuitive Surgical price target raised to $451 from $421 at BTIG
- Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy
- Intuitive Surgical announces FDA clearance of revised da Vinci Xi, X labeling